HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, today announced that in conjunction with an upcoming virtual roadshow webinar taking place Tuesday, September 20, 2022, at 4:30 p.m. ET, it has released a new video that takes viewers behind the scenes for a featured look at the HeartBeam AIMIGo technology and will be shown to viewers of the webcast.
The video explores the HeartBeam AIMIGo technology, need, market opportunity and use in heart attack detection. AIMIGo is the first and only credit card-sized 12-lead output ECG device for remote heart attack detection with a 510(K) regulatory pathway. The Company expects to submit AIMIGo to the US Food and Drug Administration (FDA) for clearance by the end of the year. Once cleared the Company believes that AIMIGo can enable patients and their clinicians, for the first time outside of a medical setting, to determine if symptoms are due to a heart attack, quickly and easily, so care can be initiated, if needed. The goal of HeartBeam’s technology is to offer more accurate heart attack detection to triage patients, expedite treatment and save healthcare dollars.
The video is available in the company’s investor relations section here.
“This new video provides a compelling overview and explanation of our technologies and highlights our continued progress toward making the AIMIGo device available for remote heart attack detection,” said Branislav Vajdic, PhD, HeartBeam CEO and founder. “We look forward to sharing the video at our upcoming webinar along with recent announcements, ongoing initiatives and key 2022 and 2023 milestones.”
HeartBeam’s CEO and founder Branislav Vajdic, PhD, CFO Rick Brounstein, and Chief Business Officer Jon Hunt, PhD, will host a virtual roadshow webinar, during which they will review recent announcements, including the Company’s 510(k) application to the FDA for its HeartBeam AIMI platform technology, newly issued patent for a 12-lead electrocardiogram (ECG) patch monitor, ongoing initiatives and discuss key 2022 and 2023 milestones. The webinar will be accompanied by a presentation and followed by a question-and-answer session from webcast viewers, which can be accessed via the webcast link.
HeartBeam AIMI and AIMIGo have not yet been cleared by the FDA for marketing in the USA or other geographies.
To access the webinar, please use the following information:
|
Date: |
Tuesday September 20, 2022 |
|
Time: |
4:30 p.m. Eastern time (1:30 p.m. Pacific time) |
|
Dial-in: |
1-877-704-4453 |
|
International Dial-in: |
1-201-389-0920 |
|
Conference Code: |
13732771 |
|
Webcast: |
https://viavid.webcasts.com/starthere.jsp?ei=1569585&tp_key=156ad0b0f4 |
A telephone replay will be available approximately two hours after the call and will run through December 20, 2022, by dialing 1-844-512-2921 from the U.S., or 1-412-317-6671 from international locations, and entering replay pin number: 13732771. The replay can also be viewed through the webinar webcast link above and the presentation utilized during the call will be available in the company’s investor relations section here.